RESUMO
INTRODUCTION: Transgender men and women in Nigeria experience many barriers in accessing HIV prevention and treatment services, particularly given the environment of transphobia (including harassment, violence and discrimination) and punitive laws in the country. HIV epidemic control in Nigeria requires improving access to and quality of HIV services for key populations at high risk, including transgender men and women. We assessed how stigma influences HIV services for transgender people in Lagos, Nigeria. METHODS: In-depth interviews (IDIs) and focus group discussions were conducted with transgender men (n = 13) and transgender women (n = 25); IDIs were conducted with community service organization (CSO) staff (n = 8) and healthcare providers from CSO clinics and public health facilities (n = 10) working with the transgender population in March 2021 in Lagos. Content analysis was used to identify how stigma influences transgender people's experiences with HIV services. RESULTS AND DISCUSSION: Three main findings emerged. First, gender identity disclosure is challenging due to anticipated stigma experienced by transgender persons and fear of legal repercussions. Fear of being turned in to authorities was a major barrier to disclose to providers in facilities not affiliated with a transgender-inclusive clinic. Providers also reported difficulty in eliciting information about the client's gender identity. Second, respondents reported lack of sensitivity among providers about gender identity and conflation of transgender men with lesbian women and transgender women with being gay or men who have sex with men, the latter being more of a common occurrence. Transgender participants also reported feeling disrespected when providers were not sensitive to their pronoun of preference. Third, HIV services that are not transgender-inclusive and gender-affirming can reinforce stigma. Both transgender men and women spoke about experiencing stigma and being refused HIV services, especially in mainstream public health facilities, as opposed to transgender-inclusive CSO clinics. CONCLUSIONS: This study highlights how stigma impedes access to appropriate HIV services for transgender men and women, which can have a negative impact along the HIV care continuum. There is a need for transgender-inclusive HIV services and competency trainings for healthcare providers so that transgender clients can receive appropriate and gender-affirming HIV services.
Assuntos
Infecções por HIV , Minorias Sexuais e de Gênero , Pessoas Transgênero , Feminino , Identidade de Gênero , Infecções por HIV/epidemiologia , Acessibilidade aos Serviços de Saúde , Homossexualidade Masculina , Humanos , Masculino , Nigéria , Estigma SocialRESUMO
BACKGROUND: This study aimed to help the Namibian government understand the impact of Treat All implementation (started on April 1, 2017) on key antiretroviral therapy (ART) outcomes, and how this transition impacts progress toward the UNAIDS's 90-90-90 HIV targets. METHODS: We collected clinical records from two separate cohorts (before and after treat-all) of ART patients in 10 high- and medium-volume facilities in 6 northern Namibia districts. Each cohort contains 12-month data on patients' scheduled appointments and visits, health status, and viral load results. We also measured patients' wait time and perceptions of service quality using exit interviews with 300 randomly selected patients (per round). We compared ART outcomes of the two cohorts: ART initiation within 7 days from diagnosis, loss to follow-up (LTFU), missed scheduled appointments for at least 30 days, and viral suppression using unadjusted and adjusted analyses. RESULTS: Among new ART clients (on ART for less than 3 months or had not yet initiated treatment as of the start date for the ART record review period), rapid ART initiation (within 7 days from diagnosis) was 5.2 times higher after Treat All than that among clients assessed before the policy took effect [AOR: 5.2 (3.8-6.9)]. However, LTFU was higher after Treat All roll-out compared to before Treat All [AOR: 1.9 (1.3-2.8)]. Established ART clients (on ART treatment for at least three months at the start date of the ART record review period) had over 3 times greater odds of achieving viral suppression after Treat All roll-out compared to established ART clients assessed before Treat All [AOR: 3.1 (1.6-5.9)]. CONCLUSIONS AND RECOMMENDATIONS: The findings indicate positive effect of the "Treat All" implementation on ART initiation and viral suppression, and negative effect on LTFU. Additionally, by April 2018, Namibia seems to have reached the UNAIDS's 90-90-90 targets.
Assuntos
Fármacos Anti-HIV/administração & dosagem , Erradicação de Doenças/normas , Epidemias/prevenção & controle , Infecções por HIV/tratamento farmacológico , Implementação de Plano de Saúde/estatística & dados numéricos , Adulto , Erradicação de Doenças/métodos , Feminino , Infecções por HIV/sangue , Infecções por HIV/diagnóstico , Infecções por HIV/epidemiologia , Humanos , Estudos Longitudinais , Perda de Seguimento , Masculino , Pessoa de Meia-Idade , Namíbia/epidemiologia , Guias de Prática Clínica como Assunto , Estudos Retrospectivos , Resultado do Tratamento , Carga Viral/efeitos dos fármacosRESUMO
The syntheses and crystal structures of sixteen compounds containing the monoanion of 3,5-pyrazoledicarboxylic acid (H(2)PzDCA) and ammonium-based counterions are reported. The cations contain short-chain alkyl, long-chain alkyl, phenyl, and chloro-, methoxy-, and amine-substituted aryl groups. Self-complementary HPzDCA intermolecular hydrogen bonds create nearly planar sheets, to which the cations connect through hydrogen bonds. Twelve of the structures exhibit virtually identical hydrogen-bonded layers, but the distance between layers varies from 9.33 to 14.10 A (+/-20 %), depending on the cation. The comparison of the sixteen structures leads to the identification of a building block (HPzDCA) that creates remarkably reproducible, lamellar structures despite substantial changes in the counterion.